GO Main Menu Go Main Contents Go Bottom Menu
  • 15
    Truxima™, the first biosimilar mAb in oncology, gr..
    22 February 2017, Incheon, South KoreaCelltrion Healthcare today announced that the European Commission has approved TruximaTM(biosimilar rituximab) for all indications of reference rituximab in the European Union (EU). Truxima™ is the first biosimil…
  • 14
    Celltrion Healthcare releases positive results fro..
    The primary outcome from a RCT in Crohn’s disease shows biosimilar infliximab is comparable to reference infliximab in terms of efficacy and safety 17thFebruary 2017, Barcelona, Spain.Today at the 12thCongress of the European Crohn’s and Colitis O…
  • 13
    Lancet Publishes Full Data-Set from Influential NO..
    Data show that switching from reference infliximab to biosimilar infliximab (CT-P13) is safe and effective across all indications Friday, January 202017.Detailed results from NOR-SWITCH, a randomized, double-blind, switching study ofbiosimilar inf…
  • 12
    New statement from European Crohn’s Colitis Organi..
    09 December 2016, Incheon, South Korea.Celltrion Healthcare welcomes the publication of the latest position paper from the European Crohn’s Colitis Organisation (ECCO) on the use of biosimilars for inflammatory bowel disease (IBD), which supports swi…
  • 11
    Celltrion Healthcare presents positive results for..
    Pivotal study shows equivalence in pharmacokinetic and safety data between CT-P10 and reference rituximab 5thDecember 2016, San Diego, United States.New data presented at the 2016 American Society of Hematology (ASH) Annual Meeting demonstrate tha…
  • 10
    Celltrion Healthcare showcases data supporting eff..
    Experts caution that data only apply to biosimilars studied 14thNovember 2016, Washington, United States.New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of…
  • 9
    Norwegian government’s independent NOR-SWITCH stud..
    Data presented at UEG Week 2016 confirm that switching to biosimilar infliximab is not inferior to continued treatment with originator and that cost-savings may improve patient access 19thOctober 2016, Vienna, Austria.New data presented at the 2016 …
  • 8
    Celltrion Healthcare announces its commitment to d..
    News follows recent FDA approval ofInflectraTM(biosimilar infliximab, other brand name Remsima®), now the first and only biosimilar monoclonal antibody (mAb) approved in the US INCHEON, REPUBLIC OF KOREA,5July 2016 –Celltrion Healthcare, a global …
  • 7
    Switching to Remsima®▼ (infliximab) from originato..
    Physician view of monoclonal antibody biosimilars increasingly positive as real-world evidence and experience grows[1] 18thMarch 2016, Amsterdam, Netherlands.Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight co…
  • 6
    No difference in efficacy or immunogenicity follow..
    New data show comparable efficacy and safety to originator infliximab in both biologic-naïve and switch patients 28 October 2015, Barcelona, Spain. New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patie…